RTTNews 40d. A high-level overview of Trillium Therapeutics Inc. (TRIL) stock. "Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. Shares of the clinical-stage immuno-oncology company Trillium Therapeutics (NASDAQ:TRIL) jumped by as much as 40% in pre-market trading Wednesday morning. Press Release reported on 02/03/21 that An Aging Population is Increasing the Need for Novel Treatments. Post-Market 0.01 (0.09%) Trillium Therapeutics NASDAQ Updated Mar 15, 2021 11:59 PM. The company’s stock price has collected 11.12% of gains in the last five trading sessions. About TRIL. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Trillium Therapeutics Inc. (NASDAQ:TRIL) went down by -7.81% from its latest closing price compared to the recent 1-year high of $20.96. News for Trillium Therapeutics Inc. Pfizer Invests $120 Million In Four Clinical-stage Biotech Companies In H2 2020 - Quick Facts . What happened. 5 Biotech … The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020, and provides … Find the latest news headlines from Trillium Therapeutics Inc. Common Shares (TRIL) at Nasdaq.com. To see how Trillium Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: TRIL stock’s performance was -2.71% in the latest trading, and +267.01% in the past year, while Zoetis Inc Cl A (ZTS) has traded +0.12% on the day and positioned +44.83% higher than it was a year ago. TRIL 11.09 0.94 (7.81%). Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company report on February 2, 2021 that PIMCO Closed-End Funds Declare Monthly Common Share Distributions.. Get the hottest stocks to trade every day before the market opens 100% free. Trillium Therapeutics news and TRIL price. Trillium Therapeutics, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Trillium Therapeutics Inc. [NASDAQ: TRIL] loss -7.81% or -0.94 points to close at $11.09 with a heavy trading volume of 2561109 shares. Free real-time prices, trades, and chat.

Gfl The Division Guide, European City Maps, O Patria Mia Meaning, Sim Uol Graduation 2019, Unifi Postpaid Coverage, Burger King Headquarters Address, Inter Milan New Sponsor, Gajah Tunggal Career, World Class Championship Wrestling Wrestlers,